Selected Publications
Traxler, EA, Komar, C, Saari, M, Thrasher, M, Qin, K, Khandros, E, Hotan, Q, Abdulmalik, O, Shao, C, Chen, Q, Minn, AJ, Keller, CA, Shi, J, Blobel, GA.: Genome-scale CRISPR-Cas12a screen identifies novel fetal hemoglobin regulators. The American Society of Hematology Annual Meeting, San Diego, CA. : 2023.
Sayani, FA, Liu, M, Frimpong, Y, Peslak, SA, Traxler, EA, Cohen, J, Russell, JE, Kwiatkowski, JL.: Adults with transfusion-dependent thalassemia have variable clinical profiles depending on where they receive care: thalassemia treatment center vs community. The American Society of Hematology Annual Meeting, San Diego, CA. : 2023.
Cheng, A, Traxler, EA, Peslak, SA, Cohen, J, Russell, JE, Sayani, FA.: Patients with non-transfusion-dependent thalassemia may evolve to transfusion-dependent thalassemia in adulthood. The American Society of Hematology Annual Meeting, San Diego, CA. : 2023.
Peslak, SA, Abbas, T, Khandros, E, Traxler, EA, Abdulmalik, O, Giardine, B, Keller, CA, Hardison, R, Shi, J, Blobel, GA.: Protein phosphatase 6 complex: novel regulator of fetal hemoglobin and potential therapeutic target in sickle cell disease. The American Society of Hematology Annual Meeting, San Diego, CA. : 2023.
Elizabeth A Traxler, Elizabeth O Hexner.: Running interferon interference in treating PV/ET: meeting unmet needs Hematology Am Soc Hematol Educ Program
(1): 463-468,2021.
Ji, X, Jha A, Humenik J, Ghanem LR, Kromer A, Duncan-Lewis C, Traxler E, Weiss MJ, Barash Y, Liebhaber SA.: RNA-binding proteins PCBP1 and PCBP2 are critical determinants of murine erythropoiesis. Mol Cell Biol
41 (9): e0066820.,2021.
Halaby R, Cuker A, Yui J, Matthews A, Ishaaya E, Traxler E, Domenico C, Cooper T, Tierney A, Niami P, van der Rijst N, Adusumalli S, Gutsche J, Giri J, Pugliese S, Hecht THE, Pishko AM.: Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: a retrospective cohort study. J Thromb Haemost
19 (6): 1533-1545,2021.
Traxler EA, Thom CS, Yao Y, Paralkar V, Weiss MJ.: Nonspecific inhibition of erythropoiesis by short hairpin RNAs. Blood
131 (24): 2733-2736,2018.
Traxler EA, Yao Y, Wang YD, Woodard KJ, Kurita R, Nakamura Y, Hughes JR, Hardison RC, Blobel GA, Li C, Weiss MJ.: A genome-editing strategy to treat -hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med
22 (9): 987-90,2016.
Bui HM, Enis D, Robcuic MR, Nurmi HJ, Cohen J, Chen M, Yang Y, Dhillon V, Johnson K, Zhang H, Kirkpatrick R, Traxler E, Anisimov A, Alitalo K, Kahn ML.: Anisimov A, Alitalo K, Kahn ML. Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD. J Clin Invest
126 (6): 2167-80,2016.
Academic Contact Information
Perelman Center for Advanced Medicine
1 South Pavilion
3400 Civic Center Blvd
Phildelphia ,
PA
19104
Patient appointments: 800-789-7366